{"id":"oseltamivir-phosphate-for-oral-suspension","safety":{"commonSideEffects":[{"rate":"10","effect":"Nausea"},{"rate":"8","effect":"Vomiting"},{"rate":"5","effect":"Abdominal pain"},{"rate":"2","effect":"Headache"},{"rate":"3","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL1200340","moleculeType":"Small molecule","molecularWeight":"410.40"},"_dailymed":{"setId":"11cf45d4-0e6c-4408-bbe6-5ed94468cf2e","title":"OSELTAMIVIR PHOSPHATE FOR ORAL SUSPENSION (OSELTAMIVIR PHOSPHATE) POWDER, FOR SUSPENSION [ORYZA PHARMACEUTICALS INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Oseltamivir is a prodrug that is converted to its active form (oseltamivir carboxylate) in the body. The active metabolite inhibits influenza neuraminidase, an enzyme on the viral surface that cleaves sialic acid receptors, thereby trapping newly formed virus particles on the cell surface and preventing their release and dissemination to other cells.","oneSentence":"Oseltamivir phosphate is a neuraminidase inhibitor that blocks the release of influenza virus particles from infected cells, preventing viral spread.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:24:51.105Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of acute uncomplicated influenza A and B infection in patients 2 weeks of age and older"},{"name":"Prophylaxis of influenza A and B in patients 1 year of age and older"}]},"trialDetails":[{"nctId":"NCT07095257","phase":"PHASE3","title":"Study to Assess the Safety and Efficacy of ZX-7101A for Oral Suspension in Chinese Pediatric Participants 2 to 11 Years of Age With Influenza","status":"RECRUITING","sponsor":"Nanjing Zenshine Pharmaceuticals","startDate":"2025-10-13","conditions":"Respiratory Viral Infection","enrollment":168},{"nctId":"NCT06669351","phase":"PHASE3","title":"Study to Assess the Safety and Efficacy of ZX-7101A in Children Aged 5-11 Years With Influenza","status":"TERMINATED","sponsor":"Nanjing Zenshine Pharmaceuticals","startDate":"2024-10-31","conditions":"Respiratory Viral Infection","enrollment":98},{"nctId":"NCT05297968","phase":"PHASE1","title":"Study on the Human Bioequivalence of Oseltamivir Phosphate For Oral Suspension","status":"COMPLETED","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2021-05-13","conditions":"Healthy Subjects","enrollment":72}],"_emaApprovals":[],"_faersSignals":[{"count":10,"reaction":"VOMITING"},{"count":8,"reaction":"HALLUCINATION"},{"count":4,"reaction":"ABNORMAL BEHAVIOUR"},{"count":4,"reaction":"CONFUSIONAL STATE"},{"count":4,"reaction":"MIDDLE INSOMNIA"},{"count":3,"reaction":"AGGRESSION"},{"count":3,"reaction":"ANXIETY"},{"count":3,"reaction":"CRYING"},{"count":3,"reaction":"SCREAMING"},{"count":2,"reaction":"ABDOMINAL PAIN UPPER"}],"_approvalHistory":[{"date":"20230214","type":"ORIG","sponsor":"EPIC PHARMA LLC","applicationNumber":"ANDA215538"},{"date":"20240702","type":"ORIG","sponsor":"PHARMOBEDIENT","applicationNumber":"ANDA217303"},{"date":"20211216","type":"SUPPL","sponsor":"ALVOGEN","applicationNumber":"ANDA208823"},{"date":"20171031","type":"ORIG","sponsor":"ALVOGEN","applicationNumber":"ANDA208823"},{"date":"20211216","type":"SUPPL","sponsor":"ALVOGEN","applicationNumber":"ANDA208823"},{"date":"20211216","type":"SUPPL","sponsor":"ALVOGEN","applicationNumber":"ANDA208823"}],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Oseltamivir Phosphate For Oral Suspension","genericName":"Oseltamivir Phosphate For Oral Suspension","companyName":"The Affiliated Hospital of Qingdao University","companyId":"the-affiliated-hospital-of-qingdao-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oseltamivir phosphate is a neuraminidase inhibitor that blocks the release of influenza virus particles from infected cells, reducing viral spread. Used for Treatment of acute uncomplicated influenza A and B infection in patients ≥2 weeks of age, Prophylaxis of influenza A and B in patients ≥1 year of age.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}